Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFIR: Safety of Insulin Glargine in T2DM
NCT00354939Phase 4Completed
- Sponsor
- Sanofi
- Start
- Oct 2003
- Primary completion
- Mar 2004
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 4 trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started Oct 2003; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00354939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354939.